



# Esophageal Cancer Screening




## Esophageal cancer: One of most lethal cancers in US

**16,980**  
new cases per year

**15,590**  
deaths per year

## Urgency to detect esophageal cancer before symptoms develop



**98 out of 100**  
*survive 5 years if*  
diagnosed asymptomatic in  
**Stage I**



**<15 out of 100**  
*survive 5 years if*  
diagnosed after symptoms in  
**Stages I, II, III or IV**

Pech et al. Gastroenterology 2014;14:652

## Collaborating to detect pancreatic cancer early

- Leveraging long-standing relationship and building on success of Cologuard®
- Significant intellectual property portfolio
- Proprietary know-how and biospecimens
- World leadership in cancer care through early detection






## Pancreatic Cancer Screening

**David A. Ahlquist, MD**  
Gastroenterologist,  
Gatton Professor of  
Digestive Diseases Research,  
Mayo Clinic



## Opportunities for early detection of esophageal cancer

- Recognizable pre-malignant condition: Barrett's esophagus
- Effective endoscopic treatment for Barrett's esophagus and earliest stage esophageal cancer
- Molecular tools offer potential to improve effectiveness of early detection



©Mayo Foundation for Medical Education and Research. All rights reserved.



## What is Barrett's esophagus?

- A premalignant change in lining of lower esophagus
- Linked to gastro-esophageal reflux (GERD), which occurs in 40% of general US population

- Broad prevalence\*

General population	3-15%
Patients with GERD	8-25%


- Readily recognized by endoscopy




©Mayo Foundation for Medical Education and Research. All rights reserved.

## Progression from Barrett's esophagus to cancer


- Histological progression
  - Long pre-symptomatic window
  - Barrett's esophagus → low grade dysplasia → high grade dysplasia → cancer
- Increased cancer risk with Barrett's esophagus **11-50x**
- Lifetime cancer risk with Barrett's esophagus **5-20%**



Barrett's esophagus without dysplasia



Barrett's esophagus with dysplasia (high grade)



Mucosal cancer





## Current approaches for early detection face multiple challenges

	Barrett's Esophagus Screening	Barrett's Esophagus Dysplasia Surveillance
	Endoscopy	Endoscopy
Status	Guideline recommended in patients with GERD	Guideline recommended periodic surveillance in patients with BE (random biopsies)
Challenges	Poor adherence	50% miss rate for cancer and focal high grade dysplasia by conventional (every 2cm) random biopsies*

Barrett's Esophagus  
Random biopsies frequently miss focal dysplasia



 Focal dysplasia  
 Random biopsies

## Our solution: A clinical application of esophageal brushing

- Evaluate and monitor Barrett's esophagus
- Endoscopic brushing of Barrett's segment
- More representative and accurate than random biopsies
- Assay of methylated DNA markers to determine presence of dysplasia or cancer

Esophageal brushing  
to detect  
Barrett's dysplasia





 Focal dysplasia

## Using endoscopic brushing to detect Barrett's esophagus-related dysplasia and cancer

- Addresses clinical need to increase sensitivity
- Potential to improve surveillance outcomes
  - Better cancer prevention by improved dysplasia detection
  - Reduced cancer mortality by improved early stage detection
  - Lower treatment-related morbidity as early detection allows endoscopic Rx
- Health economics are driven by enhanced detection over biopsy alone

## Our approach to successful early detection in Barrett's esophagus

- Identified and secured best-in-class markers
  - Whole methylome discovery
  - On tissue validation, best markers highly discriminant (AUC ~1)\*
- Demonstrated feasibility
  - BE dysplasia and early-stage EAC detection from whole esophageal brushing
  - 3-marker panel: sensitivity 81% any dysplasia, 100% early EAC\*\*
- Optimize marker combinations and assay methods
- Validate in clinical case-control study



# Mayo Clinic's prospective esophageal brushing study

## Primary Aim

Assess accuracy of methylated DNA markers in esophageal brushings to detect BE-related esophageal cancer and dysplasia



## N=300

Normal esophagus (100)



BE without dysplasia (100)




BE with dysplasia: LG, HG, or mucosal EAC (100)




## Biospecimens Collected

esophageal brushings, sponge-on-string




# Effective endoscopic options to treat and prevent esophageal cancer

Endoscopic curative removal  
of early cancer



endoscopic mucosal resection

Endoscopic ablation



radio frequency


Endoscopic ablation



cryotherapy


## Opportunities for early detection in Barrett's esophagus with new molecular tools

- Endoscopic brushing (near-term)
  - Dysplasia surveillance
- Sponge-on-string (longer-term)
  - Population screening
    - Early studies suggest feasibility\*
    - Optimal markers and methods needed
  - Dysplasia surveillance
    - Early studies suggest feasibility
    - Optimal markers and methods needed



## Paving the way to esophageal cancer screening in patients

- Initiating clinical trial with Mayo Clinic
- Evaluating regulatory pathway
- Building powerful economic story for Medicare and commercial payers





## US market opportunity for esophageal cancer early detection

	Total Number of Patients in Addressable Population Per Year	US Market Opportunity
<b>Dysplasia surveillance</b> (every 2 years for diagnosed Barrett's patients)	1M+	\$500M+

